Raffaele Colombo: ADC history.

Quoting Raffaele Colombo, Principal Scientists at Zyme Works on X/Twitter:

“Maytansine was isolated in the early ‘70s and tested in several clinical trials until 1984. Two ADC payloads derived from it, DM1 and DM4. T-DM1 was approved in 2013 and Mirvetuximab in 2022. But not so easy: 23 other maytansinoid ADCs got discontinued in the past 22 years! Camptothecin and auristatin ADCs for another time. Part of the T-DM1 history, the Refuse To File (RTF) letter for the accelerated approval of T-DM1 in 2010.”

Source: Raffaele Colombo/Twitter.